NEK2 has shown it is involved in some different cancers: NEK2 promotes aerobic glycolysis in multiple myeloma [45]; targeting NEK2 attenuates glioblastoma growth and radioresistance [46]; NEK2 can be a prognostic biomarker of hepatocellular carcinoma [47]. This evidence concerns the gene NEK2 and AL amyloidosis.